Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash

About this episode

Alan Bash discusses the commercialization of Carvykti, a leading CAR T therapy for multiple myeloma, and shares insights from his experience in the biotech industry.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we're speaking with Alan Bash, President, Carvykti, at Legend Biotech, about how Carvykti became a blockbuster, category-leading CAR T therapy for multiple myeloma. Alan talks about manufacturing and delivering an autologous cell therapy at commercial scale, Legend Biotech's partnership with Johnson & Johnson, lessons he learned at Bristol Myers Squibb, Checkmate Pharmaceuticals, and ...

People in this episode

Host: Ben Comer

Guest: Alan Bash

Topics covered

• CAR T therapy
• biotech commercialization
• manufacturing
• partnerships
• multiple myeloma

Keywords

• CAR T therapy
• Carvykti
• Legend Biotech
• multiple myeloma
• biotech partnerships
• cell therapy
• manufacturing

Mentioned in this episode

Organizations: Legend Biotech, Johnson & Johnson, Bristol Myers Squibb, Checkmate Pharmaceuticals

Products: Carvykti

More episodes of Business Of Biotech

• The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry · June 8, 2026 · 1h 24m
• Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D. · June 1, 2026 · 50 min
• Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane · May 25, 2026 · 55 min
• Scaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D. · May 18, 2026 · 51 min
• Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D. · May 11, 2026 · 54 min
• From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D. · May 4, 2026 · 56 min